ReportWire

Tag: providers

  • Adult ADHD Is the Wild West of Psychiatry

    Adult ADHD Is the Wild West of Psychiatry

    In October, when the FDA first announced a shortage of Adderall in America, the agency expected it to resolve quickly. But five months in, the effects of the shortage are still making life tough for people with attention-deficit hyperactivity disorder who rely on the drug. Stories abound of frustrated people going to dozens of pharmacies in search of medication each month, only to come up short every time. Without treatment, students have had a hard time in school, and adults have struggled to keep up at work and maintain relationships. The Adderall shortage has ended, but the widely used generic versions of the drug, known as amphetamine mixed salts, are still scarce.

    A “perfect storm” of factors—manufacturing delays, labor shortages, tight regulations—is to blame for the shortage, David Goodman, an ADHD expert and a psychiatry professor at the Johns Hopkins University School of Medicine, told me. And they have all been compounded by the fact that the pandemic produced a surge in Americans who want Adderall. The most dramatic changes occurred among adults, according to a recent CDC report on stimulant prescriptions, with increases in some age groups of more than 10 percent in just a single year, from 2020 to 2021. It’s the nature of the spike in demand for Adderall—among adults—that has some ADHD experts worried about “whether the demand is legitimate,” Goodman said. It’s possible that at least some of these new Adderall patients, he said, are getting prescriptions they do not need.

    The problem is that America has no standard clinical guidelines for how doctors should diagnose and treat adults with ADHD—a gap the CDC has called a “public health concern.” When people come in wanting help for ADHD, providers have “a lot of choices about what to use and when to use it, and those parameters have implications for good care or bad care,” Craig Surman, a psychiatry professor and an ADHD expert at Harvard and the scientific coordinator of adult-ADHD research at Massachusetts General Hospital, told me. The stimulant shortage will end, but even then, adults with ADHD may not get the care they need.

    For more than 200 years, symptoms related to ADHD—such as difficulty focusing, inability to sit still, and fidgeting—have largely been associated with children and teenagers. Doctors widely assumed that kids would grow out of it eventually. Although symptoms become “evident at a very early period of life,” one Scottish physician wrote in 1798, “what is very fortunate [is that] it is generally diminished with age.” For some people, ADHD symptoms really do get better as they enter adulthood, but for most, symptoms continue. The focus on children persists today in part because of parental pressure. Pediatricians have had to build a child-focused ADHD model, Surman said, because parents come in and say, “What are we going to do with our kid?” As a result, treating children ages 4 to 18 for ADHD is relatively straightforward: Clear-cut clinical guidelines from the American Academy of Pediatrics specify the need for rigorous psychiatric testing that rules out other causes and includes reports about the patient from parents and teachers. Treatment usually involves behavior management and, if necessary, medication.

    But there is no equivalent playbook for adults with ADHD in the U.S.—unlike in other developed nations, including the U.K. and Canada. In fact, the disorder was only recently acknowledged within the field of adult psychiatry. One reason it went overlooked for so long is because ADHD can sometimes look different in kids compared with adults: Physical hyperactivity tends to decrease with age as opposed to, say, emotional or organizational problems. “The recognition that ADHD is a life-span disorder that persists into adulthood in most people has really only happened in the last 20 years,” Margaret Sibley, a psychiatry professor at the University of Washington School of Medicine, told me. And the field of adult psychiatry has been slow to catch up. Adult ADHD was directly addressed for the first time in DSM-5—the American Psychiatric Association’s diagnostic bible—in 2013, but the criteria described there still haven’t been translated into practical instructions for clinicians.

    Addressing adult ADHD isn’t as simple as adapting children’s standards for grown-ups. A key distinction is that the disorder impairs different aspects of an adult’s life: Whereas a pediatrician would investigate ADHD’s impact at school or at home, a provider evaluating an adult might delve into its effects at work or in romantic relationships. Sources of information differ too: Parents and teachers can shed light on a child’s situation, but “you wouldn’t call the parent of a 40-year-old to get their take on whether the person has ADHD,” Sibley said. Providers usually rely instead on self-reporting—which isn’t always accurate. Complicating matters, the symptoms of ADHD tend to be masked by other cognitive issues that arise in adulthood, such as those caused by depression, drug use, thyroid problems, or hormonal shifts, Sibley said: “It’s a tough disorder to diagnose, because there’s no objective test.” The best option is to perform a lengthy psychiatric evaluation, which usually involves reviewing symptoms, performing a medical exam, taking the patient’s history, and assessing the patient using rating scales or checklists, according to the APA.

    Without clinical guidelines or an organizational body to enforce them, there is no pressure to uphold that standard. Virtual forms of ADHD care that proliferated during the pandemic, for example, were rarely conducive to lengthy evaluations. A major telehealth platform that dispensed ADHD prescriptions, Cerebral, has been investigated for sacrificing medical rigor for speedy treatment and customer satisfaction, potentially letting people without ADHD get Adderall for recreational use. In one survey, 97 percent of Cerebral users said they’d received a prescription of some kind. Initial consultations with providers lasted just half an hour, reported The Wall Street Journal; former employees feared that the company’s rampant stimulant-prescribing was fueling an addiction crisis. “It’s impossible to do a comprehensive psychiatric evaluation in 30 minutes,” Goodman said. (Cerebral previously denied wrongdoing and no longer prescribes Adderall or other stimulants.)

    The bigger problem is that too few providers are equipped to do those evaluations in the first place. Because adult ADHD was only recently recognized, most psychiatrists working today received no formal training in treating the disorder. “There’s a shortage of expertise,” Surman said. “It’s a confusing space where, at this point, consumers often are educating providers.” The dearth of trained professionals means that many adults seeking help for ADHD are seen by providers, including primary-care doctors, social workers, and nurse practitioners, who lack the experience to offer it. “It’s a systemic issue,” Sibley said, “not that they’re being negligent.”

    The lack of trained providers opens up the potential for inadequate or even dangerous care. Adderall is just one of many stimulants used to treat ADHD, and choosing the right one for a patient can be challenging—and not all people with ADHD need or want to take them. But even the most well-intentioned health-care professionals may be unprepared to evaluate patients properly. The federal government considers Adderall a highly addictive Schedule II drug, like oxycodone and fentanyl, and the risks of prescribing it unnecessarily are high: Apart from dependency, it can also cause issues such as heart problems, mood changes, anxiety, and depression. Some people with ADHD might be better off with behavioral therapy or drugs that aren’t stimulants. Unfortunately, it can be all too easy for inexperienced providers to start a patient on these drugs and continue treatment. “If I give stimulants to the average person, they’ll say their mood, their thinking, and their energy are better,” Goodman said. “It’s very important not to make a diagnosis based on the response to stimulant medication.” But the uptick in adults receiving prescriptions for those drugs since at least 2016 is a sign that this might be happening.

    The fact that adult ADHD is surging may soon lead to change. Last year, the American Professional Society of ADHD and Related Disorders began drafting the long-needed guidelines. The organization’s goal is to standardize care and treatment for adult ADHD across the country, said Goodman, who is APSARD’s treasurer. Establishing standards could have “broad, sweeping implications” beyond patient care, he added: Their existence could compel more medical schools to teach about adult ADHD, persuade insurance companies to cover treatment, and pressure lawmakers to include it in workplace policies.

    A way out of this mess, however long overdue, is only going to become even more necessary. Nearly 5 percent of adults are thought to have the disorder, but less than 20 percent of them have been diagnosed or have received treatment (compared with about 77 percent of children). “You have a much larger market of recognized and untreated adults, and that will continue to increase,” Goodman said. Women—who, like girls, are historically underdiagnosed—will likely make up a substantial share. Adults with ADHD may have suffered in silence in the past, but a growing awareness of the disorder, made possible by ongoing destigmatization, will continue to boost the ranks of people who want help. On social media, ADHD influencers abound, as do dedicated podcasts on Spotify.

    Until guidelines are published—and embedded into medical practice—the adult-ADHD landscape will remain chaotic. Some people will continue to get Adderall prescriptions they don’t need, and others may be unable to get an Adderall prescription they do need. Rules alone couldn’t have prevented the shortage, and they won’t stop it now. But in more ways than one, their absence means that many people who need help for ADHD are unable to receive it.

    Yasmin Tayag

    Source link

  • Computers May Have Cracked the Code to Diagnosing Sepsis

    Computers May Have Cracked the Code to Diagnosing Sepsis

    This article was originally published in Undark Magazine.

    Ten years ago, 12-year-old Rory Staunton dove for a ball in gym class and scraped his arm. He woke up the next day with a 104-degree Fahrenheit fever, so his parents took him to the pediatrician and eventually the emergency room. It was just the stomach flu, they were told. Three days later, Rory died of sepsis after bacteria from the scrape infiltrated his blood and triggered organ failure.

    “How does that happen in a modern society?” his father, Ciaran Staunton, asked me.

    Each year in the United States, sepsis kills more than a quarter million people—more than stroke, diabetes, or lung cancer. One reason for all this carnage is that if sepsis is not detected in time, it’s essentially a death sentence. Consequently, much research has focused on catching sepsis early, but the condition’s complexity has plagued existing clinical support systems—electronic tools that use pop-up alerts to improve patient care—with low accuracy and high rates of false alarm.

    That may soon change. Back in July, Johns Hopkins researchers published a trio of studies in Nature Medicine and npj Digital Medicine showcasing an early-warning system that uses artificial intelligence. The system caught 82 percent of sepsis cases and significantly reduced mortality. While AI—in this case, machine learning—has long promised to improve health care, most studies demonstrating its benefits have been conducted using historical data sets. Sources told me that, to the best of their knowledge, when used on patients in real time, no AI algorithm has shown success at scale. Suchi Saria, the director of the Machine Learning and Healthcare Lab at Johns Hopkins University and the senior author of the studies, said in an interview that the novelty of this research is how “AI is implemented at the bedside, used by thousands of providers, and where we’re seeing lives saved.”

    The Targeted Real-Time Early Warning System scans through hospitals’ electronic health records—digital versions of patients’ medical histories—to identify clinical signs that predict sepsis, alert providers about at-risk patients, and facilitate early treatment. Leveraging vast amounts of data, TREWS provides real-time patient insights and a unique level of transparency in its reasoning, according to the Johns Hopkins internal-medicine physician Albert Wu, a co-author of the study.

    Wu says that this system also offers a glimpse into a new age of medical electronization. Since their introduction in the 1960s, electronic health records have reshaped how physicians document clinical information; nowadays, however, these systems primarily serve as “an electronic notepad,” he added. With a series of machine-learning projects on the horizon, both from Johns Hopkins and other groups, Saria says that using electronic records in new ways could transform health-care delivery, providing physicians with an extra set of eyes and ears—and helping them make better decisions.

    It’s an enticing vision, but one in which Saria, the CEO of the company developing TREWS, has a financial stake. This vision also discounts the difficulties of implementing any new medical technology: Providers might be reluctant to trust machine-learning tools, and these systems might not work as well outside controlled research settings. Electronic health records also come with many existing problems, from burying providers under administrative work to risking patient safety because of software glitches.

    Saria is nevertheless optimistic. “The technology exists; the data is there,” she says. “We really need high-quality care-augmentation tools that will allow providers to do more with less.”


    Currently, there’s no single test for sepsis, so health-care providers have to piece together their diagnoses by reviewing a patient’s medical history, conducting a physical exam, running tests, and relying on their own clinical impressions. Given such complexity, over the past decade, doctors have increasingly leaned on electronic health records to help diagnose sepsis, mostly by employing a rules-based criteria—if this, then that.

    One such example, known as the SIRS criteria, says a patient is at risk of sepsis if two of four clinical signs—body temperature, heart rate, breathing rate, white-blood-cell count—are abnormal. This broadness, although helpful for catching the various ways sepsis might present itself, triggers countless false positives. Take a patient with a broken arm: “A computerized system might say, ‘Hey, look, fast heart rate, breathing fast.’ It might throw an alert,” says Cyrus Shariat, an ICU physician at Washington Hospital in California. The patient almost certainly doesn’t have sepsis but would nonetheless trip the alarm.

    These alerts also appear on providers’ computer screens as a pop-up, which forces them to stop whatever they’re doing to respond. So, despite these rules-based systems occasionally reducing mortality, there’s a risk of alert fatigue, where health-care workers start ignoring the flood of irritating reminders. According to M. Michael Shabot, a surgeon and the former chief clinical officer of Memorial Hermann Health System, “It’s like a fire alarm going off all the time. You tend to be desensitized. You don’t pay attention to it.”

    Already, electronic records aren’t particularly popular among doctors. In a 2018 survey, 71 percent of physicians said that the records greatly contribute to burnout, and 69 percent said that they take valuable time away from patients. Another 2016 study found that, for every hour spent on patient care, physicians have to devote two extra hours to electronic health records and desk work. James Adams, the chair of the Department of Emergency Medicine at Northwestern University, calls electronic health records a “congested morass of information.”

    But Adams also says that the health-care industry is at an inflection point to transform the files. An electronic record doesn’t have to simply involve a doctor or nurse putting data in, he says; instead, it “needs to transform to be a clinical-care-delivery tool.” With their universal deployment and real-time patient data, electronic records could warn providers about sepsis and various other conditions—but that will require more than a rules-based approach.

    What doctors need, according to Shabot, is an algorithm that can integrate various streams of clinical information to offer a clearer, more accurate picture when something’s wrong.


    Machine-learning algorithms work by looking for patterns in data to predict a particular outcome, like a patient’s risk of sepsis. Researchers train the algorithms on existing data sets, which helps the algorithms create a model for how that world works and then make predictions on new data sets. The algorithms can also actively adapt and improve over time, without the interference of humans.

    TREWS follows this general mold. The researchers first trained the algorithm on historical electronic-records data so that it could recognize early signs of sepsis. After this testing showed that TREWS could have identified patients with sepsis hours before they actually got treatment, the algorithm was deployed inside hospitals to influence patient care in real time.

    Saria and Wu published three studies on TREWS. The first tried to determine how accurate the system was, whether providers would actually use it, and if use led to earlier sepsis treatment. The second went a step further to see if using TREWS actually reduced patient mortality. And the third interviewed 20 providers who tested the tool on what they thought about machine learning, including what factors facilitate versus hinder trust.

    In these studies, TREWS monitored patients in the emergency department and inpatient wards, scanning through their data—vital signs, lab results, medications, clinical histories, and provider notes—for early signals of sepsis. (Providers could do this themselves, Saria says, but it might take them about 20 to 40 minutes.) If the system suspected organ dysfunction based on its analysis of millions of other data points, it flagged the patient and prompted providers to confirm sepsis, dismiss the alert, or temporarily pause the alert.

    “This is a colleague telling you, based upon data and having reviewed all this person’s chart, why they believe there’s reason for concern,” Saria says. “We very much want our frontline providers to disagree, because they have ultimately their eyes on the patient.” And TREWS continuously learns from these providers’ feedback. Such real-time improvements, as well as the diversity of data TREWS considers, are what distinguish it from other electronic-records tools for sepsis.

    In addition to these functional differences, TREWS doesn’t alert providers with incessant pop-up boxes. Instead, the system uses a more passive approach, with alerts arriving as icons on the patient list that providers can click on later. Initially, Saria was worried this might be too passive: “Providers aren’t going to listen. They’re not going to agree. You’re mostly going to get ignored.” However, clinicians responded to 89 percent of the system’s alerts. One physician interviewed for the third study described TREWS as less “irritating” than the previous rules-based system.

    Saria says that TREWS’s high adoption rate shows that providers will trust AI tools. But Fei Wang, an associate professor of health informatics at Weill Cornell Medicine, is more skeptical about how these findings will hold up if TREWS is deployed more broadly. Although he calls these studies first-of-a-kind and thinks their results are encouraging, he notes that providers can be conservative and resistant to change: “It’s just not easy to convince physicians to use another tool they are not familiar with,” Wang says. Any new system is a burden until proven otherwise. Trust takes time.

    TREWS is further limited because it only knows what’s been inputted into the electronic health record—the system is not actually at the patient’s bedside. As one emergency-department physician put it, in an interview for the third study, the system “can’t help you with what it can’t see.” And even what it can see is filled with missing, faulty, and out-of-date data, according to Wang.

    But Saria says that TREWS’s strengths and limitations complement those of health-care providers. Although the algorithm can analyze massive amounts of clinical data in real time, it will always be limited by the quality and comprehensiveness of the electronic health record. The goal, Saria adds, is not to replace physicians, but to partner with them and augment their capabilities.


    The most impressive aspect of TREWS, according to Zachary Lipton, an assistant professor of machine learning and operations research at Carnegie Mellon University, is not the model’s novelty, but the effort it must have taken to deploy it on 590,736 patients across five hospitals over the course of the study. “In this area, there is a tremendous amount of offline research,” Lipton says, but relatively few studies “actually make it to the level of being deployed widely in a major health system.” It’s so difficult to perform research like this “in the wild,” he adds, because it requires collaborations across various disciplines, from product designers to systems engineers to administrators.

    As such, by demonstrating how well the algorithm worked in a large clinical study, TREWS has joined an exclusive club. But this uniqueness may be fleeting. Duke University’s Sepsis Watch algorithm, for one, is currently being tested across three hospitals following a successful pilot phase, with more data forthcoming. In contrast with TREWS, Sepsis Watch uses a type of machine learning called deep learning. Although this can provide more powerful insights, how the deep-learning algorithm comes to its conclusions is unexplainable—a situation that computer scientists call the black-box problem. The inputs and outputs are visible, but the process in between is impenetrable.

    On the one hand, there’s the question of whether this is really a problem: Doctors don’t always know how drugs work, Adams says, “but at some point, we have to trust what the medicine is doing.” Lithium, for example, is a widely used, effective treatment for bipolar disorder, but nobody really understands exactly how it works. If an AI system is similarly useful, maybe interpretability doesn’t matter.

    Wang suggests that that’s a dangerous conclusion. “How can you confidently say your algorithm is accurate?” he asks. After all, it’s difficult to know anything for sure when a model’s mechanics are a black box. That’s why TREWS, a simpler algorithm that can explain itself, might be a more promising approach. “If you have this set of rules,” Wang says, “people can easily validate that everywhere.”

    Indeed, providers trusted TREWS largely because they could see descriptions of the system’s process. Of the clinicians interviewed, none fully understood machine learning, but that level of comprehension wasn’t necessary.


    In machine learning, although the specific algorithmic design is important, the results have to speak for themselves. By catching 82 percent of sepsis cases and reducing time to antibiotics by 1.85 hours, TREWS ultimately reduced patient deaths. “This tool is, No. 1, very good; No. 2, received well by clinicians; and No. 3, impacts mortality,” Adams says. “That combination makes it very special.”

    However, Shariat, the ICU physician at Washington Hospital in California, was more cautious about these findings. For one, these studies only compared patients with sepsis who had the TREWS alert confirmed within three hours to those who didn’t. “They’re just telling us that this alert system that we’re studying is more effective if someone responds to it,” Shariat says. A more robust approach would have been to conduct a randomized controlled trial—the gold standard of medical research—where half of patients got TREWS in their electronic record while the other half didn’t. Saria says that randomization would have been difficult to do given patient-safety concerns, and Shariat agrees. Even so, he says that the absence “makes the data less rigorous.”

    Shariat also worries that the sheer volume of alerts, with about two out of three being false positives, might contribute to alert fatigue—and potentially overtreatment with fluids and antibiotics, which can lead to serious medical complications such as pulmonary edema and antibiotic resistance. Saria acknowledges that TREWS’s false-positive rate, although lower than that of existing electronic-health-record systems, could certainly improve, but says it will always be crucial for clinicians to continue to use their own judgment.

    The studies also have a conflict of interest: Saria is entitled to revenue distribution from TREWS, as is Johns Hopkins. “If this goes prime time, and they sell it to every hospital, there’s so much money,” Shariat says. “It’s billions and billions of dollars.”

    Saria maintains that these studies went through rigorous internal and external review processes to manage conflicts of interest, and that the vast majority of study authors don’t have a financial stake in this research. Regardless, Shariat says it will be crucial to have independent validation to confirm these findings and ensure the system is truly generalizable.

    The Epic Sepsis Model, a widely used algorithm that scans through electronic records but doesn’t use machine learning, is a cautionary example here, according to David Bates, the chief of general internal medicine at Brigham and Women’s Hospital. He explains that the model was developed at a few health systems with promising results before being deployed at hundreds of others. The model then deteriorated, missing two-thirds of patients with sepsis and having a concerningly high false-positive rate. “You can’t really predict how much the performance is going to degrade,” Bates says, “without actually going and looking.”

    Despite the potential drawbacks, Orlaith Staunton, Rory’s mother, told me that TREWS could have saved her son’s life. “There was complete breakdown in my son’s situation,” she said; none of his clinicians considered sepsis until it was too late. An early-warning system that alerted them about the condition, she added, “would make the world of difference.”

    After Rory’s death, the Stauntons started the organization End Sepsis to ensure that no other family would have to go through their pain. In part because of their efforts, New York State mandated that hospitals develop sepsis protocols, and the CDC launched a sepsis-education campaign. But none of this will ever bring back Rory, Ciaran Staunton said: “We will never be happy again.”

    This research is personal for Saria as well. Almost a decade ago, her nephew died of sepsis. By the time it was discovered, there was nothing his doctors could do. “It all happened too quickly, and we lost him,” she says. That’s precisely why early detection is so important—life and death can be mere minutes away. “Last year, we flew helicopters on Mars,” Saria says, “but we’re still freaking killing patients every day.”

    Simar Bajaj

    Source link

  • Health 2.0 and Mad*Pow Announce Agenda for 2017 HxRefactored

    Health 2.0 and Mad*Pow Announce Agenda for 2017 HxRefactored

    Design & Technology-focused Conference on June 20th & 21st Explores Improving
    Health Experiences through Human-centered Design and Tech

    Press Release



    updated: May 2, 2017

    Mad*Pow and Health 2.0 today announced the final agenda for the HxRefactored 2017 Conference being held on June 20-21, 2017, at the Royal Sonesta Hotel in Cambridge, MA. HxRefactored is a revolutionary design and technology conference, gathering more than 600 cross-disciplinary thinkers from around the world for two days of thought-provoking panels, workshops, and discussions on how to improve the quality of health experiences. Conference speakers and attendees apply design, science, evidence, and theory to re-imagine the entire health journey and find new ways to deliver that vision. Tickets to attend the conference can be purchased at https://2017.hxrefactored.com.

    HxRefactored keynotes, workshops, and panels will touch on the most pressing issues and innovative ideas of the day. Topics explored at this year’s conference will include:

    “HxRefactored is a truly unique event because it is designed to explore opportunities to humanize our healthcare and deliver value to the people we serve and ways to put those ideas into action.”

    Amy Cueva, Founder and Chief Experience Officer of Mad*Pow

    • Designing for Mental Health
    • Creating a Culture of Health
    • Data Security and Privacy
    • Improving Clinician Experiences
    • Motivation and Health Behavior Change
    • Culture of Innovation
    • Breaking Down the Silos
    • The Future of Technology
    • Navigating the Health System
    • Patient Experiences of the Future
    • Designing for Vulnerable and At-Risk Populations
    • Tech for the Aging Population
    • Pharma Innovation
    • Blockchain: The Now and the Future
    • Co-Creation and Participatory Design
    • Journey Mapping and Service Design
    • Organizational Design and Training

    Speakers headlining this year’s HxRefactored include:

    • Aneesh Chopra, President, NavHealth
    • Robin Farmanfarmaian, Author, The Patient as CEO
    • Bakul Patel, Associate Director of Digital Health, FDA
    • Kathleen Howland, Professor, Berklee College of Music
    • Busy Burr, VP, Innovation and Health, Humana Health Ventures
    • Bryan Mazlish, Chief Technology Officer, Bigfoot Biomedical, Inc.
    • John Torous, Co-Director of Digital Psychiatry at BIDMC, Beth Israel Deaconess Medical Center
    • John Weiss, Co-Founder/CEO, Human Design
    • Aron Semle, CEO, upBed
    • Matthew Holt, Co-Chairman, Health 2.0
    • Amy Cueva, Founder & Chief Experience Officer, Mad*Pow
    • Sumit Nagpal, Co-Founder & CEO, LumiraDx, Inc.
    • Steven Ledbetter, CEO and Co-Founder, Habitry
    • Wolf Shlagman, CEO, Care Angel
    • Zac Jiwa, CEO, MI7
    • Juhan Sonin, Creative Sandpaper, goinvo, MIT
    • Patricia Beirne, Design and Innovation Creative Lead, Memorial Sloan Kettering
    • Bradford Diephuis, CEO, Herald Health
    • Natasha Awasthi, Head of Product, Medal
    • Charles Hillman, Founder and CEO, GrandCare
    • Cory Kidd, Founder and CEO, Catalia Health
    • Linda Sanches, Senior Advisor, HIT and Privacy Policy, Office for Civil Rights, HHS
    • Abbie Barbir, Senior Architect, Aetna
    • Ted Tanner, CTO, PokitDok
    • Dustin DiTommaso, SVP Behavior Change Design, Mad*Pow
    • Jay Gupta, Co-Founder, RxRelax

    “HxRefactored draws speakers and panelists who live and work at the intersection of health, design, and technology,” says Health 2.0 Co-Chairman Matthew Holt. “Their unique perspective can help shed light on solutions to some of the most challenging problems in our health system. The conference offers attendees an opportunity to hear this perspective and to get involved in the effort to make our health system more effective.”

    “HxRefactored is a truly unique event because it is designed to explore opportunities to humanize our healthcare and deliver value to the people we serve and ways to put those ideas into action,” said Amy Cueva, Mad*Pow Founder, and Chief Experience Officer. “Attendees at this event hear a wealth of exciting, groundbreaking ideas and walk out of the conference motivated to create real change in the healthcare system.”

    For more information on the conference and to register for HxRefactored, visit our website.

    About Mad*Pow

    Mad*Pow is a design agency that improves the experience people have with technology, organizations and each other. The company’s mission is to help people improve their health, achieve financial well-being, learn, and connect. Using human-centered design, Mad*Pow collaborates with clients to understand and empathize with the people they serve. Through this collaboration, Mad*Pow delivers an experience that addresses customer needs across channels, and throughout the entire journey. Founded in 2000, Mad*Pow has partnered with industry leaders including Cigna, John Hancock, Pearson, and Google, and has received honors for design excellence by the Webby Awards, MITX, and the W3C. In addition to HXR, Mad*Pow also hosts the Center for Health Experience Design (http://www.centerhxd.com) which will serve as a resource for design and experiential innovation in health.

    About Health 2.0

    Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, thought leadership roundtables, developer competitions, pilot programs, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care.

    Contact:

    Liz Griffith
    lgriffith@madpow.com
    SOURCE Mad*Pow

    Tarek Cotran
    Tarek@health2con.com
    SOURCE Health 2.0

    Source: Mad*Pow, Health 2.0

    Source link